In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells
作者: Lei ZhangZhengming WangTungalagtamir KhishignyamTing ChenChang ZhouZhe ZhangMeihua JinRan WangYuling QiuDexin Kong
作者单位: 1Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin, 300070, China
2Department of pharmacy, Tianjin Haihe Hospital, Tianjin, 300350, China
刊名: Biomedicine & Pharmacotherapy, 2018, Vol.103 , pp.1069-1078
来源数据库: Elsevier Journal
DOI: 10.1016/j.biopha.2018.04.089
关键词: VoxtalisibLeukemiaG1 arrestMultidrug resistance
原始语种摘要: Abstract(#br)Current treatment strategies for leukemia still have some limitations such as severe side effects and drug resistance. Less toxic and more effective drugs for leukemia patients are therefore expected. In the present study, the efficacy of a dual PI3K/mTOR inhibitor, Voxtalisib, on acute myeloid leukemia (AML) cell line HL60 and chronic myeloid leukemia (CML) cell line K562, as well as their Adriamycin (ADR)-selected multi drug resistance (MDR) counterparts HL60/ADR and K562/A02, was investigated. Voxtalisib exhibited potent anti-proliferative activity on these four cell lines dose-dependently, with IC 50 values as 2.23 μM for HL60, 4.79 μM for HL60/ADR, 4.20 μM for K562 and 3.90 μM for K562/A02 cells. Voxtalisib arrested cell cycle progression at G1 phase in all cell lines by...
全文获取路径: Elsevier  (合作)
影响因子:2.068 (2012)

  • leukemia 白血病
  • ADR ADd noRmalized
  • cells 麻风细胞
  • arrest 制动器
  • myeloid 骨髓的
  • CML Common Mode Logic
  • AML Micro Switch
  • activity 活度
  • Adriamycin 阿霉素
  • their 他们的